Reappraisal on pharmacological and mechanical treatments of heart failure

Abstract

Heart failure (HF) is a highly frequent disorder with considerable morbidity, hospitalization, and mortality; thus, it invariably places pressure on clinical and public health systems in the modern world. There have been notable advances in the definition, diagnosis, and treatment of HF, and newly developed agents and devices have been widely adopted in clinical practice. Here, this review first summarizes the current emerging therapeutic agents, including pharmacotherapy, device-based therapy, and the treatment of some common comorbidities, to improve the prognosis of HF patients. Then, we discuss and point out the commonalities and areas for improvement in current clinical studies of HF. Finally, we highlight the gaps in HF research. We are looking forward to a bright future with reduced morbidity and mortality from HF.

Bioimpedance Vector Analysis for Heart Failure: Should We Put It on the Agenda?

“…In addition, the hydration state measured by BIVA in the AHF group was significantly decreased 72 h after diuretic medication treatment and at discharge ( 28 ). Routine laboratory testing, such as brain natriuretic peptide (BNP)/N-terminal pro BNP (NT-pro BNP) ( 2 , 40 ), is of great clinical significance for the reaction of peripheral fluid accumulation. BIVA significantly improved the prediction ability of cardiovascular events at 3 months (AUC = 0.97) when combined with clinical symptoms and signs ( 27 ).…”

Advances in Exosomes Derived from Different Cell Sources and Cardiovascular Diseases

“…BioMed Research International BioMed Research International infarction [90]. Heart failure is the end-stage state of various cardiovascular diseases [91,92], and heart failure pathological condition altered the miRNA cargos of cardiac-derived exosomes and impaired their regenerative activities. It may be related to miR-21-5p, the exosome released from explant-derived cardiac stromal cells, contributing to heart repair by enhancing angiogenesis and cardiomyocyte survival through the phosphatase and tensin homolog/Akt pathway [93].…”

“…Exosomes released by chronically hypoxic cardiac precursor cells deliver a pool of miRNAs (miR-15b, miR-17, miR-20a, miR-103, miR-199a, miR-210, and miR-292) that enhance angiogenesis, reduce profibrotic gene expression, preserve myocardial contractile function, and improve cardiac function in the early hours after the onset of acute myocardial infarction [ 90 ]. Heart failure is the end-stage state of various cardiovascular diseases [ 91 , 92 ], and heart failure pathological condition altered the miRNA cargos of cardiac-derived exosomes and impaired their regenerative activities. It may be related to miR-21-5p, the exosome released from explant-derived cardiac stromal cells, contributing to heart repair by enhancing angiogenesis and cardiomyocyte survival through the phosphatase and tensin homolog/Akt pathway [ 93 ].…”

Effect of therapy on the dynamics of collagen metabolism markers in older patients with heart failure with mid-range ejection fraction and coronary artery disease

“…Небиволол был выбран как препарат третьего поколения, обладающий самой высокой β 1 -селективностью, и дополнительными сосудорасширяющими и антиоксидантными свойствами. В настоящее время он применяется в лечении ХСН у лиц пожилого и старческого возраста, в т. ч. с коморбидной патологией [9]. Вопрос о том, приводят ли эти преимущества к улучшению отдаленного клинического результата, замедлению прогрессирования ХСНпФВ на фоне ИБС и какие механизмы при этом включаются у данной категории больных, в доступной литературе не описаны.…”